SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
+2.5%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.28B
AUM Growth
+$1.28B
(-12%)
Cap. Flow
-$120M
Cap. Flow
% of AUM
-9.41%
Top 10 Holdings %
Top 10 Hldgs %
66.69%
Holding
88
New
13
Increased
13
Reduced
24
Closed
17
Top Buys
| 1 |
INZY
Inozyme Pharma
INZY
|
$53.3M |
| 2 |
CMPI
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
|
$41.5M |
| 3 |
Amgen
AMGN
|
$28.4M |
| 4 |
NCNA
NuCana
NCNA
|
$17.2M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
$14.9M |
Top Sells
| 1 |
PRNB
Principia Biopharma Inc. Common Stock
PRNB
|
$84.7M |
| 2 |
Gilead Sciences
GILD
|
$31M |
| 3 |
Coherus Oncology, Inc. Common Stock
CHRS
|
$27.5M |
| 4 |
Merck
MRK
|
$21.6M |
| 5 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$17.8M |
Sector Composition
| 1 | Healthcare | 98.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Natera
NTRA
$23.1B
| $224M | 16.61% | 3,100,560 | – | – |
|
2
Ascendis Pharma
ASND
$11.8B
| $171M | 12.7% | 1,109,874 | – | – |
|
|
KRTX
3
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $151M | 11.19% | 1,952,441 +66,839 | +4% | +$5.17M |
|
4
Y-mAbs Therapeutics
YMAB
$388M
| $84.2M | 6.25% | 2,194,278 | – | – |
|
|
INZY
5
DELISTED
Inozyme Pharma
INZY
| $53.3M | 3.95% | +2,028,308 | New | +$53.3M |
|
|
CMPI
6
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
| $41.5M | 3.08% | +3,606,707 | New | +$41.5M |
|
|
AKUS
7
DELISTED
Akouos, Inc. Common Stock
AKUS
| $34.7M | 2.57% | 1,515,073 | – | – |
|
8
United Therapeutics
UTHR
$13.8B
| $32.4M | 2.4% | 320,959 +16,397 | +5% | +$1.66M |
|
9
AbbVie
ABBV
$372B
| $29.9M | 2.22% | 341,340 +89,381 | +35% | +$7.83M |
|
|
NCNA
10
NuCana
NCNA
$6.09M
| $29M | 2.15% | 5,599,999 +3,333,333 | +147% | +$17.2M |
|
|
11
Amgen
AMGN
$155B
| $28.4M | 2.1% | +111,619 | New | +$28.4M |
|
|
GRTX
12
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
| $27.9M | 2.07% | 3,083,712 | – | – |
|
13
NextCure
NXTC
$13.5M
| $23.5M | 1.74% | 2,671,856 | – | – |
|
14
Eli Lilly
LLY
$657B
| $21.1M | 1.56% | 142,432 -6,468 | -4% | -$957K |
|
15
Insmed
INSM
$28.8B
| $19.8M | 1.47% | 615,143 +131,176 | +27% | +$4.22M |
|
|
16
BioMarin Pharmaceuticals
BMRN
$11.2B
| $19.7M | 1.46% | 258,653 +195,756 | +311% | +$14.9M |
|
17
PTC Therapeutics
PTCT
$3.92B
| $18.9M | 1.4% | 405,152 -33,118 | -8% | -$1.55M |
|
18
Jazz Pharmaceuticals
JAZZ
$7.75B
| $18.6M | 1.38% | 130,268 -113,085 | -46% | -$16.1M |
|
|
19
Merck
MRK
$210B
| $15.8M | 1.17% | 190,559 -260,619 | -58% | -$21.6M |
|
20
Merus
MRUS
$4.98B
| $15.7M | 1.17% | 1,311,039 | – | – |
|
|
ITCI
21
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $12.9M | 0.96% | 503,555 +261,647 | +108% | +$6.71M |
|
|
OBSV
22
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $11.8M | 0.87% | 4,749,623 | – | – |
|
23
Athira Pharma
ATHA
$15.3M
| $9.4M | 0.7% | +509,168 | New | +$9.4M |
|
|
OTIC
24
DELISTED
Otonomy, Inc.
OTIC
| $8.55M | 0.63% | 2,111,596 +460,185 | +28% | +$1.86M |
|
|
GWPH
25
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $8.08M | 0.6% | +82,944 | New | +$8.08M |
|